DD136738A5 - Verfahren zur herstellung neuer polypeptide - Google Patents

Verfahren zur herstellung neuer polypeptide

Info

Publication number
DD136738A5
DD136738A5 DD77198869A DD19886977A DD136738A5 DD 136738 A5 DD136738 A5 DD 136738A5 DD 77198869 A DD77198869 A DD 77198869A DD 19886977 A DD19886977 A DD 19886977A DD 136738 A5 DD136738 A5 DD 136738A5
Authority
DD
German Democratic Republic
Prior art keywords
preparing new
new polypeptides
polypeptides
preparing
new
Prior art date
Application number
DD77198869A
Other languages
English (en)
Inventor
Anand S Dutta
Barrington J A Furr
Michael B Giles
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of DD136738A5 publication Critical patent/DD136738A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
DD77198869A 1976-05-11 1977-05-11 Verfahren zur herstellung neuer polypeptide DD136738A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (1)

Publication Number Publication Date
DD136738A5 true DD136738A5 (de) 1979-07-25

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
DD77198869A DD136738A5 (de) 1976-05-11 1977-05-11 Verfahren zur herstellung neuer polypeptide

Country Status (27)

Country Link
US (1) US4100274A (de)
JP (1) JPS52136172A (de)
AT (2) AT379400B (de)
AU (1) AU508025B2 (de)
BE (1) BE854467A (de)
BG (1) BG60740B2 (de)
CA (1) CA1101844A (de)
CH (2) CH627151A5 (de)
CS (1) CS199673B2 (de)
DD (1) DD136738A5 (de)
DE (1) DE2720245C2 (de)
DK (1) DK149596C (de)
ES (1) ES458691A1 (de)
FI (1) FI64139C (de)
FR (1) FR2351092A1 (de)
GB (1) GB1524747A (de)
HU (1) HU179990B (de)
IE (1) IE44426B1 (de)
IL (1) IL52014A (de)
NL (2) NL191793C (de)
NO (2) NO147304C (de)
NZ (1) NZ183931A (de)
PL (2) PL104362B1 (de)
SE (2) SE437837B (de)
SU (1) SU910116A3 (de)
YU (1) YU40672B (de)
ZA (1) ZA772433B (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (de) * 1988-12-20 1990-06-29
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
IL93693A (en) * 1989-03-10 2000-01-31 Endorech Inc Pharmaceutical compositions for the treatment of estrogen sensitive diseases
GR1001164B (el) * 1989-07-07 1993-05-24 Endorecherche Inc Παραγωγα αρρενογονου ορμονης προς χρησιν εις την αναστολην δραστηριοτητος της στεροειδους ορμονης φυλου
HUT60139A (en) * 1989-07-07 1992-08-28 Endorecherche Inc Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
RU2141967C1 (ru) * 1992-05-21 1999-11-27 Андорешерш Инк. ИНГИБИТОРЫ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ТЕСТОСТЕРОН 5α-РЕДУКТАЗЫ
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
EP1008656A4 (de) 1996-06-13 2000-09-20 Itoham Foods Inc Verfahren zur herstellung von lh-rh derivaten
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
CA2994779C (en) 2001-02-19 2020-08-25 Novartis Ag Use of 40-o-(2-hydroxyethyl)-rapamycin for inhibiting growth of a solid tumour of the brain other than lymphatic cancer
RU2318517C2 (ru) 2001-05-16 2008-03-10 Новартис Аг Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
MXPA04011384A (es) 2002-05-16 2005-02-14 Novartis Ag Uso de agentes de union del receptor edg en cancer.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
BRPI0412259B1 (pt) 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
ME02125B (me) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ552029A (en) * 2004-06-25 2009-01-31 Takeda Pharmaceutical Metastin derivatives and use thereof
EP2415484B1 (de) * 2004-09-17 2014-06-18 Durect Corporation Anhaltende Lokalanästhetikumzusammensetzung mit SAIB
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CA2594477C (en) 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP1773870B1 (de) 2005-05-03 2009-12-16 Novetide Ltd. Verfahren zur herstellung von peptidderivaten
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GT200600430A (es) 2005-09-27 2007-05-21 Compuestos de carboxiamina y metodos de uso de los mismos
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
WO2007128820A1 (en) 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
JP2011506318A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
JP5490092B2 (ja) 2008-03-24 2014-05-14 ノバルティス アーゲー アリールスルホンアミドをベースとするマトリクスメタロプロテアーゼ阻害剤
WO2009118305A1 (en) 2008-03-26 2009-10-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
BRPI0922301A2 (pt) * 2008-11-28 2019-02-26 Novartis Ag combinações de inibidor de hsp90
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
EP2467383A1 (de) 2009-08-20 2012-06-27 Novartis AG Heterocyclische oximverbindungen
IN2012DN01693A (de) 2009-08-26 2015-06-05 Novartis Ag
EP2475668A1 (de) 2009-09-10 2012-07-18 Novartis AG Etherderivate bicyclischer heteroaryle
ES2487628T3 (es) 2009-11-04 2014-08-22 Novartis Ag Derivados de sulfonamida heterocíclica útiles como inhibidores de MEK
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
AU2012265844A1 (en) 2009-12-08 2013-05-02 Novartis Ag Heterocyclic sulfonamide derivatives
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
CN107693794A (zh) 2010-06-16 2018-02-16 恩多研究公司 治疗或预防雌激素相关疾病的方法
CN102947275A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 哌啶基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
US20130090342A1 (en) 2010-06-17 2013-04-11 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
EP2721008B1 (de) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituierte isochinolinone als p53 (mdm2 or mdm4) inhibitoren
KR20140025530A (ko) 2011-06-27 2014-03-04 노파르티스 아게 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
EP2785717B1 (de) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidinverbindungen
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
US20150148377A1 (en) 2011-12-22 2015-05-28 Novartis Ag Quinoline Derivatives
EP2794588A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
EP2794590A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
WO2013096060A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US9126979B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
WO2013188763A1 (en) 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
BR112015003058A2 (pt) 2012-08-13 2017-07-04 Novartis Ag derivados bicíclicos de heteroaril cicloalquildiamina como inibidores de tirosina quinases do baço (syk)
ES2654143T3 (es) 2012-10-02 2018-02-12 Gilead Sciences, Inc. Inhibidores de desmetilasas de histonas
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
EP2948453B1 (de) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
AP2015008676A0 (en) 2013-02-27 2015-08-31 Epitherapeutics Aps Inhibitors of histone demethylases
US9572885B2 (en) 2013-03-15 2017-02-21 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
RU2016133285A (ru) 2014-01-15 2018-02-20 Новартис Аг Фармацевтические комбинации
EP3122728A4 (de) 2014-03-28 2017-10-25 Calitor Sciences, LLC Substituierte heteroarylverbindungen und verfahren zur verwendung davon
WO2015153498A1 (en) 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibitors of histone demethylases
BR112016022499A2 (pt) 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
MX2017002451A (es) 2014-08-27 2017-05-23 Gilead Sciences Inc Compuestos y metodos para inhibir histona desmetilasas.
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
AU2017444054B2 (en) 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2021059266A1 (en) * 2019-09-26 2021-04-01 S.I.S. Shulov Innovative Science Ltd. Anti-aging compositions and methods of use thereof
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (de) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Also Published As

Publication number Publication date
AT365562B (de) 1982-01-25
DK149596C (da) 1987-01-05
ATA335877A (de) 1985-05-15
CH627151A5 (de) 1981-12-31
PL104362B1 (pl) 1979-08-31
YU117277A (en) 1983-02-28
AT379400B (de) 1985-12-27
ZA772433B (en) 1978-03-29
NL7705130A (nl) 1977-11-15
NO149586C (no) 1984-05-16
SU910116A3 (ru) 1982-02-28
BG60740B2 (bg) 1996-01-31
SE437837B (sv) 1985-03-18
ATA217979A (de) 1981-06-15
NO147304C (no) 1983-03-16
PL108860B1 (en) 1980-05-31
ES458691A1 (es) 1978-08-16
NO149586B (no) 1984-02-06
BE854467A (fr) 1977-11-10
PL197889A1 (pl) 1978-02-13
FR2351092A1 (fr) 1977-12-09
IL52014A (en) 1979-11-30
DK149596B (da) 1986-08-04
JPS6113480B2 (de) 1986-04-14
SE7705432L (sv) 1977-11-12
IE44426B1 (en) 1981-11-18
DE2720245C2 (de) 1986-09-25
NO822984L (no) 1977-11-14
CS199673B2 (en) 1980-07-31
SE8007763L (sv) 1980-11-05
NO147304B (no) 1982-12-06
SE437993B (sv) 1985-03-25
NL970002I1 (nl) 1997-03-03
YU40672B (en) 1986-04-30
FI64139C (fi) 1983-10-10
DK207977A (da) 1977-11-12
FR2351092B1 (de) 1980-02-22
JPS52136172A (en) 1977-11-14
NL970002I2 (nl) 1997-05-01
NL191793B (nl) 1996-04-01
US4100274A (en) 1978-07-11
IL52014A0 (en) 1977-07-31
CH629475A5 (de) 1982-04-30
IE44426L (en) 1977-11-11
NO771644L (no) 1977-11-14
NZ183931A (en) 1979-03-16
AU508025B2 (en) 1980-03-06
DE2720245A1 (de) 1977-11-24
HU179990B (en) 1983-01-28
CA1101844A (en) 1981-05-26
AU2468177A (en) 1978-11-02
FI771480A (de) 1977-11-12
NL191793C (nl) 1996-08-02
GB1524747A (en) 1978-09-13
FI64139B (fi) 1983-06-30

Similar Documents

Publication Publication Date Title
DD136738A5 (de) Verfahren zur herstellung neuer polypeptide
AT383143B (de) Verfahren zur herstellung neuer antiviraler polypeptide
DD134642A5 (de) Verfahren zur herstellung neuer 1-aryloxy-2-hydroxy-3-alkylenaminopropane
DD129997A5 (de) Verfahren zur herstellung neuer antibiotischer praeparate zur pharmazeutischen verwendung
DD132488A5 (de) Verfahren zur herstellung von reinem methyl-tertiaer-butylaether
AT359217B (de) Verfahren zur herstellung neuer peptid-derivate
DD129103A5 (de) Verfahren zur herstellung von n-phosphonomethylglycin
AT373577B (de) Verfahren zur herstellung neuer mercaptoacylpeptide
AT364095B (de) Verfahren zur herstellung neuer peptidderivate
ATA60577A (de) Verfahren zur herstellung neuer polypeptidderivate
DD129443A5 (de) Verfahren zur herstellung von indazolyl-(4)-oxypropanolaminen
DD133949A5 (de) Verfahren zur herstellung neuer benzopyranderivate
ATA845575A (de) Verfahren zur herstellung neuer substituierter benzophenone
ATA804377A (de) Verfahren zur herstellung eines neuen polypeptides
DD131556A5 (de) Verfahren zur herstellung von 5-m-tolyoxyuracil
DD134351A5 (de) Verfahren zur herstellung neuer pyridobenzodiazepinonen
DD132431A5 (de) Verfahren zur herstellung von aryloxy-1-amino-3-propanolen-2
DD131558A5 (de) Verfahren zur herstellung neuer indolizinderivate
AT343125B (de) Verfahren zur herstellung von 3-phenylpyridazon- (6)
AT372075B (de) Verfahren zur herstellung neuer polypeptide bzw. polypeptidderivate
AT371104B (de) Verfahren zur herstellung neuer polypeptide
DD128270A5 (de) Verfahren zur herstellung neuer azofarbstoffe
DD131088A5 (de) Verfahren zur herstellung von diaminoalkoxybenzolen
ATA78881A (de) Verfahren zur herstellung neuer polypeptide
DD130416A4 (de) Verfahren zur herstellung von o-nitrobenzylbromid

Legal Events

Date Code Title Description
RPI Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
RPV Change in the person, the name or the address of the representative (searches according to art. 11 and 12 extension act)